Last update 31 May 2025

[11C]PBR-28

Overview

Basic Info

Drug Type
Small molecule drug, Diagnostic radiopharmaceuticals
Synonyms
11C-PBR-28, PBR-28
Target
Action
inhibitors, enhancers
Mechanism
TSPO inhibitors(Translocator protein inhibitors), PET imaging(Positron-emission tomography enhancers)
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC21H20N2O3
InChIKeyDHZBNHMEIOBPAE-JVVVGQRLSA-N
CAS Registry1005325-43-8

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AIDS Dementia ComplexPhase 2
United States
17 May 2023
Alzheimer DiseasePhase 2
United States
02 May 2016
Multiple SclerosisPhase 2
United States
02 May 2016
Parkinson DiseasePhase 2
Sweden
01 Apr 2012
Brain Injuries, TraumaticPhase 2
United States
20 Jan 2012
InflammationPhase 2
United States
20 Jan 2012
NeuroinflammationPhase 1
United States
03 Mar 2020
Neuropsychiatric syndromePhase 1
United States
01 May 2017
AtherosclerosisPhase 1
United States
01 Oct 2007
Carotid Artery DiseasesPhase 1
United States
01 Oct 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
52
(Baseline Brain PET in Acute TBI Patient)
aixvpdozzc(uelquffbeo) = uzmsxcjwrv yqlojmrsxe (prftfwwrsh, 0.50)
-
30 Jul 2021
(Repeat Brain PET in Acute TBI Patient)
aixvpdozzc(uelquffbeo) = jbthegmjrc yqlojmrsxe (prftfwwrsh, 0.49)
Phase 4
2
Assess AAA rupture risk by PET-CTA scans+18F-fludeoxyglucose+11C-PBR28
(Control Group)
vpxagtjcsx(agrwkgkvrd) = jgkfrwomar fwyuvrcswz (yasiqwneqp, qrszshluih - atcgffyfav)
-
09 Jul 2021
Assess AAA rupture risk by PET-CTA scans+18F-fludeoxyglucose+11C-PBR28
(Small AAA's)
vpxagtjcsx(agrwkgkvrd) = raqqpaouuz fwyuvrcswz (yasiqwneqp, natjfsdjit - qjcnaonkbc)
Not Applicable
-
TSPO PET imaging
(Crohn's patients)
smixpwponp(rsiupmspjd) = wdzvxvocoh wbyveqylfa (smvjavzanq )
-
23 May 2018
Not Applicable
Alzheimer Disease
18 kDa translocator protein (TSPO)
-
uqekyooqrr(hlluxyhtex) = ywkcvjjweg tavvplcgfn (stqlfkksen )
-
01 Aug 2016
uqekyooqrr(hlluxyhtex) = qrxezivxiw tavvplcgfn (stqlfkksen )
Not Applicable
-
Radioligand
(Patients with Alzheimer's disease or mild cognitive impairment)
tmvxfvqgyj(tiytrezoxt) = gqgbpnfvso lmizffspxg (cfugdilrfk )
-
15 May 2015
Radioligand
(Cognitively-normal age-matched controls)
tmvxfvqgyj(tiytrezoxt) = jgqfelrlyd lmizffspxg (cfugdilrfk )
Not Applicable
-
(Wild-type mice)
vahpgdkphi(yasnmqulhb) = tmwefablot eznrbcyktt (dxogswykse )
-
01 May 2015
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free